Foscenvivint

Drug Overview

Foscenvivint (also known in research as PRI-724 or OP-724) is an advanced, experimental medicine. It belongs to a modern group of treatments known as Targeted Therapy. In the medical world, this is often called a “Smart Drug” because it is designed to seek out and block a specific broken signal inside diseased cells, rather than attacking the whole body like traditional chemotherapy.

Currently, foscenvivint is not available at standard pharmacies. It is being carefully tested in clinical trials. It is highly unique because it is being studied to treat both stubborn cancers and severe liver scarring (cirrhosis).

• Generic Name: Foscenvivint (Research codes: PRI-724, OP-724)
• US Brand Names: None (Currently an investigational drug)
• Drug Class: Wnt/Beta-catenin Signaling Pathway Inhibitor / CBP Inhibitor
• Route of Administration: Intravenous (IV) Infusion (a slow drip into a vein)
• FDA Approval Status: Investigational (Not yet approved by the FDA for general medical use)

What Is It and How Does It Work? (Mechanism of Action)

To understand how this Smart Drug works, imagine your cells have a “grow and divide” switch. This switch is controlled by a communication system called the Wnt signaling pathway.

In healthy cells, this switch is strictly controlled. But in many cancers and liver diseases, the switch gets stuck in the “ON” position.

At the molecular level, foscenvivint works to turn this switch off:

1. The Culprit (Beta-catenin): When the Wnt pathway is stuck on, a protein called beta-catenin builds up inside the cell. It travels deep into the center of the cell (the nucleus).
2. The Helper (CBP): Once inside the nucleus, beta-catenin looks for a helper protein called CBP (CREB-binding protein). When beta-catenin and CBP lock together, they send out a powerful signal that tells the cell to multiply rapidly or form scar tissue.
3. The Roadblock: Foscenvivint acts as a precise roadblock. It binds specifically to the CBP helper protein.
4. Stopping the Signal: Because the drug is blocking CBP, the beta-catenin cannot attach to it. Without this connection, the cell cannot read the genes that tell it to grow. The cancer cells are starved of their growth signals, and the tumor stops expanding.

FDA Approved Clinical Indications

Because foscenvivint is an investigational drug, it does not currently have official FDA-approved uses for the general public. However, it is actively being researched in clinical trials for the following areas:

Oncological Uses (Under Investigation)

• Hepatocellular Carcinoma (HCC): The most common type of liver cancer.
• Acute Myeloid Leukemia (AML) and Chronic Myeloid Leukemia (CML): Cancers of the blood and bone marrow.
• Pancreatic Cancer and Colorectal Cancer: Usually studied in patients whose tumors have stopped responding to older treatments.

Non-Oncological Uses (Under Investigation)

• Liver Cirrhosis: Severe scarring of the liver, often caused by Hepatitis C, Hepatitis B, or fatty liver disease.
• Primary Biliary Cholangitis (PBC): A chronic disease that slowly destroys the bile ducts in the liver.

Dosage and Administration Protocols

Note: Because foscenvivint is an investigational drug, dosages are determined strictly by clinical trial protocols to find the safest and most effective level. The table below represents generalized guidelines used in recent human trials.

Clinical Efficacy and Research Results

Recent clinical research (spanning 2020 to 2025) has focused heavily on foscenvivint’s unique ability to heal the liver while fighting cancer.

• Anti-Tumor Activity: In early-stage trials for liver cancer (Hepatocellular Carcinoma), foscenvivint showed promising signs of “anti-tumor activity.” This means it was able to shrink or stabilize tumors in a specific group of patients whose cancer was driven by the Wnt signaling pathway.
• Reducing Liver Scarring: For non-cancer patients, recent Phase 2 trials have tested the drug’s ability to reverse liver cirrhosis. Numerical data suggests that foscenvivint can improve liver function scores (like the ALBI score) by stopping the cells that cause liver scarring (hepatic stellate cells) from activating.
• Survival and Progression: Because the drug is still moving through Phase 1 and Phase 2 trials, massive long-term survival rates are not yet fully published. However, by stopping cancer from progressing and simultaneously improving liver health, it is considered a highly valuable candidate for future cancer care.

Safety Profile and Side Effects

Like all powerful treatments, foscenvivint can cause side effects. Because it is given directly into the blood, patients are monitored closely during the infusion.

Black Box Warning:

As an investigational medication, foscenvivint does not currently carry an FDA Black Box Warning.

Common Side Effects (>10%)

• Gastrointestinal Upset: Nausea, mild vomiting, or diarrhea.
• Fatigue: Feeling unusually tired or weak.
• Infusion Site Reactions: Mild pain, redness, or swelling where the IV needle goes into the arm.
• Elevated Liver Enzymes: Temporary spikes in blood tests that show the liver is working hard.

Serious Adverse Events

• Hepatotoxicity: Severe liver stress or damage, especially in patients who already have advanced liver cirrhosis.
• Allergic Reactions: A rare risk of a severe allergic reaction (anaphylaxis) during the IV infusion.

Management Strategies

• For Nausea: Patients are routinely given standard anti-nausea medicines before the IV drip begins to keep their stomach calm.
• For Liver Stress: You will have your blood drawn frequently. If your liver enzymes rise too high, your trial doctor will pause the medication until your liver recovers.

Connection to Stem Cell and Regenerative Medicine

Foscenvivint is currently a massive focus in the field of Cancer Stem Cell research and Regenerative Medicine.

First, tumors often have hidden “root cells” called cancer stem cells. These dangerous cells use the Wnt signaling pathway to survive standard chemotherapy, hide, and cause the cancer to grow back months or years later. By blocking this exact pathway, foscenvivint acts as a “stem cell killer,” stripping the cancer of its ability to regenerate.

Second, in the liver, the drug helps with true regenerative medicine. By blocking the Wnt pathway, the drug stops the formation of thick scar tissue (fibrosis). By clearing away the scar tissue, it gives the liver’s natural, healthy stem cells the physical space and healthy environment they need to regenerate and rebuild a functioning liver.

Patient Management and Practical Recommendations

If you are participating in a clinical trial using foscenvivint, your healthcare team will monitor you very closely.

Pre-treatment Tests to be Performed

• Comprehensive Liver Panel: Blood tests (AST, ALT, Bilirubin) to measure your exact liver health.
• Viral Screening: Blood tests to check for Hepatitis B, Hepatitis C, or HIV, as these can affect how the liver responds to the drug.
• Complete Blood Count (CBC): To ensure you have enough healthy red and white blood cells before starting.

Precautions During Treatment

• Avoid Liver Toxins: Your liver will be very sensitive during this trial. You must completely avoid alcohol and any medications that can harm the liver (including high doses of acetaminophen/Tylenol).
• Watch for Jaundice: Pay close attention to your body. If you notice your skin or the whites of your eyes turning yellow, report it to your doctor immediately.

“Do’s and Don’ts” List

• Do attend all your scheduled clinic visits for blood draws; this is the only way your doctor can protect your liver from silent stress.
• Do drink plenty of water to help your body process the medication safely.
• Do tell your trial nurse immediately if you feel itchy, hot, or dizzy while the IV drip is running.
• Don’t take any new over-the-counter herbal supplements or vitamins without asking your oncologist, as they can interfere with the trial drug.
• Don’t skip your scheduled liver scans (like FibroScans or MRIs), as they are critical to proving if the drug is successfully healing your liver or shrinking the tumor.

Legal Disclaimer

The medical information provided in this guide is intended for educational and informational purposes only. Foscenvivint (PRI-724/OP-724) is an investigational drug and is not approved by the U.S. Food and Drug Administration (FDA) or other global regulatory agencies for standard commercial use. It is only available to patients enrolled in approved clinical trials. This information should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult your oncologist or a qualified healthcare provider regarding your specific medical condition, treatment options, and clinical trial eligibility.